Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTR1D | P28221 | 18/20 | 0.51 |
| ▸ | HTR1A | P08908 | 16/20 | 0.51 |
| ▸ | HTR1B | P28222 | 16/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.51 |
| ▸ | DRD2 | P14416 | 5/20 | 0.49 |
| ▸ | HTR2A | P28223 | 4/20 | 0.49 |
| ▸ | HTR2C | P28335 | 4/20 | 0.49 |
| ▸ | HTR2B | P41595 | 4/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 4/20 | 0.49 |
| ▸ | DRD3 | P35462 | 4/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4178103 | 0.92 | HTR1D (0.50) | HTR1DHTR1AHTR1BKCNH2SLC6A4 | |
| SCHEMBL4180284 | 0.81 | HTR1D (0.48) | HTR1DHTR1AHTR1BKCNH2SLC6A4 | |
| Hydrochloric Acid SCHEMBL4174485 | 0.81 | HTR1D (0.47) | HTR1DHTR1AHTR1BKCNH2SLC6A4 | |
| SCHEMBL4174680 | 0.80 | HTR1D (0.73) | HTR1DHTR1AHTR1BKCNH2SLC6A4 | |
| Hydrochloric Acid SCHEMBL4174718 | 0.80 | HTR1D (0.72) | HTR1DHTR1AHTR1BKCNH2SLC6A4 | |
| SCHEMBL2882966 | 0.76 | HTR1A (0.71) | HTR1DHTR1AHTR1BKCNH2DRD2 | |
| SCHEMBL4174265 | 0.72 | HTR1D (0.73) | HTR1DHTR1AHTR1BKCNH2SLC6A4 | |
| SCHEMBL4167331 | 0.72 | HTR1D (0.72) | HTR1DHTR1AHTR1BKCNH2SLC6A4 | |
| SCHEMBL2304702 | 0.71 | HTR1D (0.53) | MAPTHTR1DHTR1AHTR1BKCNH2 | |
| SCHEMBL4176618 | 0.71 | HTR1D (0.72) | HTR1DHTR1AHTR1BKCNH2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | GLAXO GROUP LIMITED (GB) | 2006-11-23 | — | — | US | claimed |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED | 2009-03-19 | — | — | US | disclosed |
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | GLAXO GROUP LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| EP-1562917-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004046124-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | XDH, CYP4X1, PDHX | MAPT 2057/4885HTR1D 75/4885HTR1A 47/4885 |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | XDH, CYP4X1, PDHX | MAPT 1924/4885HTR1D 569/4885HTR1A 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.